Compositions for generating an antigen specific immune response
AssigneeHelmholtz-Zentrum fuer Infektionsforschung GmbH
InventorLars Zender
Life of this patent
Estimating the term…
Loading patent…
AssigneeHelmholtz-Zentrum fuer Infektionsforschung GmbH
InventorLars Zender
Estimating the term…
The present invention provides for the purposeful utilisation of the induction of senescence in eukaryotic cells for induction of an antigen specific immune response. Such cells can be normal cells, pre-malignant and malignant cells as well as virally or bacterially infected cells, for the generation of an immune response, preferably a cellular or humoral immune response comprising T-cells and/or B-cells, whose immune response is directed specifically against antigens from those cells in which senescence was induced and then comprises an immune response against the senescent cells itself as well as to the non-senescent counterparts harbouring the same antigens.
Senescent pre-malignant or malignant cells for use as a medicament for inducing a specific immune response against senescent and non-senescent malignant cells in a treatment against malignant cells, wherein the pre-malignant or malignant senescent cells are generated by contact with a senescence inducing agent which is selected from cytostatic compounds, ionising radiation in a dosage which is essentially lower than a dosage inducing cell death, and an expression cassette causing overexpression of a tumour suppressor gene (e.g. p53) or of an oncogene, an MDM2 inhibiting drug, a PTEN inhibiting drug, and in that the dosage is sufficient for inducing senescence in at least some malignant cells.
Pharmaceutical composition for use as a medicament in the treatment of malignant cells in a patient, the composition comprising in a pharmaceutically acceptable formulation a senescence inducing agent that is selected from cytostatic compounds and ionising radiation in a dosage which is essentially lower than a dosage inducing cell death, overexpression of a tumour suppressor gene or an oncogene and in that the dosage is sufficient for inducing senescence in at least some malignant cells.
Pharmaceutical composition for use in the medical treatment of malignant cells in a patient, the composition comprising in a pharmaceutically acceptable formulation for introduction into a patient an autologous immune cell of the patient, which immune cell is specific for the malignant cell by being contacted in vitro with a senescent malignant cell that is autologous to the patient.
Dependencies are inferred from the claim text.